Early diagnosis of Alzheimer disease with positron emission tomography

Alzheimer Disease and Associated Disorders

Volumn 14, Issue SUPPL. 1, 2000, Pages

  Jelic, Vesna ^a   Nordberg, Agneta ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

Alzheimer disease; Diagnosis; Glucose metabolism; Mild cognitive impairment; Positron emission tomography

Indexed keywords

APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; BRAIN FUNCTION; CHROMOSOME 14; CHROMOSOME 21; COGNITIVE DEFECT; CONFERENCE PAPER; DOWN SYNDROME; EARLY DIAGNOSIS; FAMILIAL DISEASE; GENE MUTATION; HUMAN; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEMPORAL LOBE;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; COGNITION DISORDERS; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; DOWN SYNDROME; HUMANS; PATIENT SELECTION; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034046639     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200000001-00016     Document Type: Conference Paper

References (59)

1. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer Disease. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 1995;274:1627-9.
2. Azari NP, Pettigrew KD, Schapiro MB, et al. Early detection of Alzheimer's disease: a statistical approach using positron emission tomographic data. J Cereb Blood Flow Metab 1993;13:438-47.
3. Corder EH, Jelic V, Basun H, et al. No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Arch Neurol 1997;54:273-7.
4. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
5. Convit A, DeLeon MJ, Tarshish C, et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobiol Aging 1997;18:131-8.
6. Dani A, Pietrini P, Furey M, et al. Brain cognition and metabolism in Down syndrome adults in association with development of dementia. Neuroreport 1996;7:2933-6.
7. DeCarli C, Atack JR, Ball MJ, et al. Postmortem regional neurofibrillary tangle densities but not senile plaques densities are related to regional cerebral metabolic rates for glucose during life in Alzheimer's disease patients. Neurodegeneration 1992;1:113-21.
8. DeLeon MJ, Ferris SH, George AE, et al. CT and PET: evaluations of normal aging and Alzheimer's disease. J Cereb Blood Flow Metab 1983;3:391-4.
9. DeLeon MJ, Golomb J, George AE, et al. The radiologic prediction of Alzheimer's disease: the atrophic hippocampal formation. Am J Neuroradiol 1993;14:897-906.
10. DeSanti S, DeLeon MJ, Rusinek H, et al. Selective medial temporal lobe pathology in cases at risk for Alzheimer's disease: diagnostic role of positron emission tomography. In: Iqbal K, Mortimer JA, Winblad B, Wisniewski HM, eds. Recent advances in Alzheimer's disease and related disorders. New York: John Wiley & Sons, 1995:173-80.
11. Diagnostic and statistical manual of mental disorders. 3rd ed. revised (DSM-III-R). Washington, DC: American Psychiatric Association, 1987.
12. Duara R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology 1986;36:879-87.
13. Ellis WG, McCulloch JR, Corley CL. Presenile dementia in Down's syndrome: ultrastructural identity with Alzheimer's disease. Neurology 1974;24:101-6.
14. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology 1991;41:1006-9.
15. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, DiChiro G. Alzheimer's disease: focal cortical changes shown by PET. Neurology 1983;33:961-5.
16. Frackowiak RSJ, Pozzilli C, Legg NJ, et al. Regional cerebral oxygen supply and utilization in dementia: a clinical and physiological study with O-15 and positron tomography. Brain 1981;104:753-78.
17. Fukuyama H, Harada K, Yamauchi H, et al. Coronal reconstruction images of glucose metabolism in Alzheimer's disease. J Neurol Sci 1991;106;128-34.
18. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease. Ann Neurol 1996;39:62-70.
19. Grady CL, Haxby JV, Horwitz B, et al. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J Clin Exp Neuropsychol 1988;10:576-96.
20. Grady CL, Haxby JV, Schlageter NL, Berg G, Rapoport SI. Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type. Neurology 1986;36:1390-2.
21. Haxby JV, Duara R, Grady CL, Cutler NR, Rapoport SI. Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. J Cereb Blood Flow Metab 1985;5:193-200.
22. Haxby JV, Grady CL, Koss E, et al. Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer type. Neurology 1988;38:1853-63.
23. Haxby JV, Grady CL, Koss E, et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol 1990;47:753-60.
24. Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord 1995;1:6-16.
25. Herholz K, Nordberg A, Salmon E, et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord 1999;10:494-504.
26. Hirono N, Mori E, Yasuda M, et al. Lack of association of apolipoprotein E ε4 allele dose with cerebral glucose metabolism in Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:362-7.
27. Jack CR, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999; 52:1397-403.
28. Jagust WJ, Eberling JL, Richardson BC, et al. The cortical topography of temporal lobe hypometabolism in early Alzheimer's disease. Brain Res 1993;629:189-98.
29. Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober B. Longitudinal studies of regional cerebral metabolism in Alzheimer disease. Neurology 1988;38:909-12.
30. Jelic V, Wahlund L-O, Almkvist O, et al. Diagnostic accuracies of quantitative EEG and PET in mild Alzheimer's disease. Alzheimer Rep 1999;5:291-8.
31. Johnson KA, Jones K, Holman BL, et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998;50:1563-71.
32. Kennedy AM, Frackowiak RSJ, Newman SK, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 1995b;186:17-20.
33. Kennedy AM, Newman S, Clegg F, et al. Imaging in dementia: longitudinal studies using positron emission tomography. Neurobiol Aging 1992;13:513.
34. Kennedy AM, Rossor MN, Frackowiak RSJ. Positron emission tomography in familial Alzheimer's disease. Alzheimer Dis Assoc Disord 1995a;9:17-20.
35. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging. Alzheimer's disease and Parkinson's disease. Ann Neurol 1996;40:399-410.
36. Mayeux R, Stern Y, Ottman R, et al. The apolipoprolem ε4 allele in patients with Alzheimer's disease. Ann Neurol 1993;34:752-4.
37. 18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans. Can J Neurol Sci 1990;17:1-11.
38. McKhann G, Drachman D, Folslein M, Katzman R, Price D, Stadlan M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
39. Mielke R, Herholz K, Grind M, Kessler J, Heiss WD. Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia 1994;5:36-41.
40. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
41. Nagy Z, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995;69:757-61.
42. Nordberg A. Functional brain imaging in Alzheimer's disease. In: Gauthier S, ed. Clinical diagnosis and management of Alzheimer's disease. 2nd ed. London: Martin Daunitz Ltd. 1999:117-32.
43. Nordberg A, Lundqvist H, Hartvig P, et al. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement Geriatr Cogn Disord 1997;8:78-84.
44. Nordberg A, Viitanen M, Almkvist O, et al. Longitudinal positron emission tomographic studies in families with chromosome 14 and 21 encoded Alzheimer's disease. In: Iqbal K. Mortimer JA, Winblad B, Wisniewski HM, eds. Research advances in Alzheimer's disease and related disorders. New York: John Wiley & Sons, 1995:243-9.
45. Ohm TG, Kirca M, Bohl J, et al. APOE polymorphism influences not only cerebral senile plaques load but also Alzheimer-type neurofibriflary tangle formation. Neuroscience 1995;66:583-7.
46. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8.
47. Pietrini P, Azari NP, Grady CL, et al. Pattern of cerebral metabolic interactions in a subject with isolated amnesia at risk for Alzheimer's disease: a longitudinal evaluation. Dementia 1993;4:94-101.
48. Pietrini P, Dam A, Furey ML, et al. Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Am J Psychiatry 1997;154: 1063-9.
49. Poline JB, Vandenberghe R, Holmes AP, Friston KJ, Frackowiak RS. Reproducibility of PET activation studies: lessons from a multicenter European experiment. Neuroimage 1996;4:34-54.
50. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N Engl J Med 1996;334:752-8.
51. Schapiro MB, Grady CL, Haxby JV. Nature of mental retardation and dementia in Down's syndrome: study with PET, CT, and neuropsychology. Neurobiol Aging 1992;13:723-4.
52. Scmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid β-peptides deposition as a consequence of apolipoprotein E genotype in late onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:9649-53.
53. 18F] FDG PET: a clinical validation of statistical parametric mapping. Neuroimage 1999;9:63-80.
54. Small GW, Komo S, La Rue A, et al. Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann N Y Acad Sci 1996;802:70-8.
55. Small GW, Mazziota JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995a;273:942-7.
56. Small GW, La Rue A, Komo S, Kaplan A, Mendelkern MA. Predictors of cognitive change in middle aged and older adults with memory loss. Am J Psychiatry 1995b;152:1757-64.
57. Szelies B, Grond M, Herholz K, Kessler J, Wullen T, Heiss W-D. Quantitative EEG mapping and PET in Alzheimer's disease. J Neurol Sci 1992;110:46-56.
58. Wahlund L-O, Basun H, Almkvist O, et al. A follow up study of the family with the Swedish APP 670/671 Alzheimer's disease mutation. Dement Geriatr Cogn Disord 1999;10:526-33.
59. Warzok RW, Kessler C, Apel G, et al. Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly. Alzheimers Dis Assoc Disord 1998;12:33-9.